Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

AIMS: To evaluate the clinical impact of the Canadian criteria for identifying patients and families at risk for hereditary renal cell carcinoma (RCC). MATERIALS AND METHODS: The Canadian hereditary RCC risk criteria were applied to patients from 16 centres in the Canadian Kidney Cancer information system (CKCis) prospective database. The primary end point was the proportion of patients who met at least one criterion. RESULTS: Between January 2011 and May 2017, 8388 patients were entered in the database; 291 had inadequate risk data; 2827 (35%) met at least one criterion for genetic testing (at-risk population). Most (83%) met just one criterion. The criterion of non-clear cell histology contributed the largest proportion of at-risk patients (59%), followed by age ≤ 45 years (28%). Sixty-one patients had documentation of genetic testing, with 56 being classified at-risk (2% of at-risk). Twenty patients (35%) of the patients at risk and tested for hereditary RCC were found to harbour a germline mutation. CONCLUSIONS: Application of the Canadian hereditary RCC risk criteria to a large prospective database resulted in 35% of patients being identified at risk for hereditary RCC who could qualify for genetic testing. However, the true incidence of hereditary RCC in this population is unknown as most patients did not have documented genetic testing carried out and, thus, the sensitivity and specificity of the criteria cannot be determined. The low proportion of at-risk patients who underwent genetic testing is disappointing and highlights that there may be gaps in reporting, knowledge and/or barriers in access to genetic testing.

Predictive factors for return of erectile function in robotic radical prostatectomy: case series from a single centre.

Postprostatectomy erectile dysfunction is a frequent complication of robotic-assisted radical prostatectomy (RARP). We attempted to retrospectively identify objective predictors of erectile recovery in a population of potent men undergoing RARP. Data for 375 consecutive patients were collected prospectively from a single surgeon in an academic institution from 2005 to 2011. Inclusion criteria were 2 years of complete follow-up, preoperative International Index of Erectile Function (IIEF) scores of ≥ 22 without erectogenic aids and no adjuvant therapy (n = 86). Patients were grouped by erectile function at 2 years as 'Recovery' (IIEF ≥ 17, n = 41) and 'non-recovery' (IIEF < 16, n = 45). Baseline and perioperative characteristics were evaluated between groups. Body mass index, operative time and gland volumes were not different between groups. Univariate analysis demonstrated that higher preoperative prostate-specific antigen, longer apical dissection time and non-nerve-sparing surgery decreased erectile recovery. Multivariable analysis demonstrated that longer apical dissection time remained an independent predictor of decreased erectile function (P < 0.001). In contrast, postoperative intracavernosal injection (ICI) was found to predict erectile recovery (P = 0.017). At 2-year follow-up, prolonged apical dissection time predicts nonrecovery and ICI rehabilitation predicts recovery of erectile function after RARP. This can inform patients' postoperative expectations. However, further studies are needed to support the findings of this exploratory analysis.